Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments

  • Cendrós, Marc
  • Catalán, Rosa|||0000-0001-7003-2401
  • Torra, Mercè
  • Penadés, Rafael|||0000-0002-1564-3717
  • González-Rodríguez, Alexandre|||0000-0003-1855-8566
  • Brunet, Mercè|||0000-0002-7154-916X
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Cullell, Natalia|||0000-0001-5118-1014
  • Serra-Llovich, Alexandre|||0000-0001-8318-851X
  • Hernandez, Marta H.
  • Arranz, María Jesús|||0000-0002-6757-9198
Traditionally, the aetiology of schizophrenia has been attributed to dopaminergic neurotransmission, but more recent information points to the role of glutamate pathways. Glutamatergic involvement in schizophrenia might be extensible to drug response. The aim of the study was to explore whether the variation in glutamate receptors, transporters and metabolism can influence the outcome of drug treatments. A total of 45 polymorphisms in the genes GRIN1, GRIN2A, GRIN2B, GRIN3A, GRIA1, GRIK2, GRM2, GRM3, GRM5, GRM8, SLC1A1, SLC1A3 and GAD1 were genotyped in 258 patients with schizophrenia. Efficacy and side effects were evaluated with the Positive and Negative Symptoms Scale and the UKU scale, respectively, at baseline and after 12 weeks. The analysis revealed associations between outcomes, including response and adverse effects and genetic variants in several genes (GAD1, GRIA1, GRIN2A, GRIN3A, GRIK2, GRM2, GRM5, GRM8 and SLC1A3). An association of rs1864205 in GRIA1 with autonomic side effects bordered statistical significance after correction for multiple comparisons. Our results suggest that genetic variation in glutamatergic pathways can influence the efficacy and safety of antipsychotic drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments

  • Arranz, María Jesús|||0000-0002-6757-9198
  • Gonzalez-Rodriguez, Alex
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Penadés, Rafael|||0000-0002-1564-3717
  • Gutierrez, Blanca
  • Ibañez, Laura
  • Arias, Barbara|||0000-0001-9181-2132
  • Brunet, Mercè|||0000-0002-7154-916X
  • Cervilla, Jorge|||0000-0001-6891-1992
  • Salazar, Juliana|||0000-0002-3581-4499
  • Catalán, Rosa|||0000-0001-7003-2401
Antipsychotic drugs fail to achieve adequate response in 30-50% of treated patients and about 50% of them develop severe and lasting side effects. Treatment failure results in poorer prognosis with devastating repercussions for the patients, carers and broader society. Our study evaluated the clinical benefits of a pharmacogenetic intervention for the personalisation of antipsychotic treatment. Pharmacogenetic information in key CYP polymorphisms was used to adjust clinical doses in a group of patients who started or switched treatment with antipsychotic drugs (PharmG+, N = 123), and their results were compared with those of a group of patients treated following existing clinical guides (PharmG-, N = 167). There was no evidence of significant differences in side effects between the two arms. Although patients who had their antipsychotic dose adjusted according to CYPs polymorphisms (PharmG+) had a bigger reduction in side effects than those treated as usual (PharmG-), the difference was not statistically significant (p.